Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
“Halfway through 2026, and Pfizer R&D continues to execute with focus and discipline. Across Oncology, Internal Medicine, Vaccines and Inflammation and Immunology, we advanced critical R&D milestones: achieving approvals, pivotal data readouts, and new study starts. A diverse, deep pipeline, moving forward with purpose.
Behind every milestone are years of rigorous science and the relentless work of our teams around the world. It’s disciplined execution, sustained across every program and every team, that will keep our pipeline delivering quarter after quarter.
Thank you to the Pfizer R&D teams and partners worldwide who are making this happen – every day, for patients everywhere.”
Other articles about Pfizer on OncoDaily.
